Introduction of Georges Mathé by Starzl, TE & Mathé, G
0041-1337/03/7508-1108/0 
TRANSPLANTATION 
Copyright © 2003 by Lippincott Williams & Wilkins, Inc. dg~1 Vol. 75, 1108, No.8, April 27, 2003 Printed in U.S.A. 
Transplantation® 
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INTRODUCTION OF GEORGES MATHE 
Professor Georges Mathe, a man of literature as well as 
science, was born in 1922 in the village of Nieure and re-
ceived his medical degree from the University of Paris in 
1950. The theme of his professional life has been the use of 
immunity to treat neoplastic disease. These efforts began in 
1958 when he obtained evidence in a mouse leukemia model 
of a graft-versus-tumor effect of transplanted hematolympho-
poietic cells (1). 
The risk of graft-versus-host disease in humans from bone 
marrow transplantation was not known at the time. In 1959, 
Mathe was presented with the possibility of determining this 
risk after a Yugoslavian nuclear reactor accident in which six 
workers were exposed to 4 to 8 Gy of total body irradiation. 
The patient with the largest dose promptly died, whereas the 
one with 4 Gy spontaneously recovered. The other four were 
rescued by Mathe with bone marrow cell infusions from non-
related donors (2). The donor cells engrafted long enough to 
allow recovery of the native bone marrow without causing 
graft-versus-host disease (GVHD). 
The experience, which defined an irradiation dosage win-
dow from which spontaneous recovery could occur, influenced 
the next step of organ transplantation. All six of the world's 
first long-surviving kidney recipients treated in Boston and 
Paris had sublethal total body irradiation in the 4 to 6 Gy 
range. Mathe's role is evident from his co-authorship of the 
classical report by Rene Kiiss (3). 
Mathe's next seminal contribution was reported in 1963 in 
the British Medical Journal (4). Thirty-six years later, the 
article was designated a milestone at the University of Cal-
ifornia, Los Angeles, consensus development conference, 
which was convened to identify the major landmarks in the 
history of clinical transplantation (5). The ll-person consen-
sus panel consisted of nine Medawar Prize recipients and 
three Nobel laureates and included the bone marrow trans-
plant pioneers Donnall Thomas and Robert Good. 
The committee's description read: "World's first prolonged 
engraftment of human allogeneic bone marrow in an adult 
recipient with leukemia conditioned with supralethal total 
body irradiation. Died without disease recurrence after 20 
months, probably from complications of GVHD." The report 
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was, in essence, the clinical fruition of Mathe's 1958 mouse 
leukemia experiments. 
Mathe now sought a less dangerous and less histocompat-
ibility-dependent approach to bone marrow transplantation. 
In his new strategy, patients were treated with large daily 
doses of antilymphocyte globulin (ALG) for 1 to 2 weeks 
before receipt of bone marrow cells from human leukocyte 
antigens mismatched and matched donors. As in the irradi-
ated Yugoslavian patients of 1959, prolonged but unstable 
mixed chimerism was produced without evidence of GVHD 
(6). Mathe concluded that the risk of GVHD is directly re-
lated to the degree of recipient cytoablation. His advocacy of 
conditioning with ALG presaged the nonmyelotoxic strate-
gies of pretreatment in tolerance induction protocols cur-
rently under extensive evaluation in several centers. 
After 1970, Mathe fixed his attention on cancer immuno-
therapy by means other than transplantation. He has been 
recognized in many ways, including receipt of numerous 
prestigious European and American awards for cancer re-
search. However, with the passage oftime, the significance of 
his preeminent pioneer contributions to transplantation has 
become increasingly apparent. 
Today, he receives the highest distinction of the Transplan-
tation Society. I am gratified and honored to present to you, 
in absentia, Professor Georges Mathe: Commander of the 
French Legion of Honor, Grand Officer of the French Na-
tional Order of Merit, recipient of the Grand Humanitarian 
Prize of France, and now a 2002 Medawar Laureate. 
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